Archive

EA NewsletterEA Newsletter
The Brain-Delivery Biotech Still Priced Like a Science Project

The Brain-Delivery Biotech Still Priced Like a Science Project

An award-winning first drug, a big cash pile, and a stock still priced like a science experiment.

EA NewsletterEA Newsletter
Two Launches, One Coverage Decision, and a $1 Billion Target

Two Launches, One Coverage Decision, and a $1 Billion Target

An eye-care company just put a $1 billion sales target on 2027. The Medicare decision is the test.

EA NewsletterEA Newsletter
An Open Door Isn't an Order, and That's Your Opportunity

An Open Door Isn't an Order, and That's Your Opportunity

A beaten-down drone maker has a new Australian sales route. Orders are the test.

EA NewsletterEA Newsletter
A Pantry Giant at a 52-Week Low With a 6.5% Yield Attached

A Pantry Giant at a 52-Week Low With a 6.5% Yield Attached

Wall Street left this fridge-aisle giant for dead. Should you grab the 6.5% yield?

EA NewsletterEA Newsletter
The November FDA Date Hiding Inside This $80B Biotech

The November FDA Date Hiding Inside This $80B Biotech

An FDA decision next month, earnings this week, and the Street is still staring at the wrong drug.

EA NewsletterEA Newsletter
Its Biggest Owner Keeps Buying, and the Stock Just Handed You a Dip

Its Biggest Owner Keeps Buying, and the Stock Just Handed You a Dip

Its biggest shareholder keeps buying, week after week. Here's the setup.

EA NewsletterEA Newsletter
This Fintech Got Cut in Half, and Tuesday's Report Tests Whether It Deserved It

This Fintech Got Cut in Half, and Tuesday's Report Tests Whether It Deserved It

A beaten-down fintech reports before Tuesday's open. Here's the setup.

EA NewsletterEA Newsletter
The AI Landlord Wall Street Won't Give Up On

The AI Landlord Wall Street Won't Give Up On

Three Wall Street desks just defended this AI landlord after a 24% slide. The stock hasn't listened yet.

EA NewsletterEA Newsletter
A Depression Drug Maker With a Phase 3 Readout Weeks Away

A Depression Drug Maker With a Phase 3 Readout Weeks Away

A mid-cap biotech is weeks away from a Phase 3 readout that could reset the thesis.

EA NewsletterEA Newsletter
The AI Optics Name Options Traders Bought Into the Selloff

The AI Optics Name Options Traders Bought Into the Selloff

A $75B AI supplier got caught in the neocloud panic. Big money is using the dip to load up.

EA NewsletterEA Newsletter
When Goldman Lifts a Target 50% in a Single Note

When Goldman Lifts a Target 50% in a Single Note

Goldman just hiked a price target 50% on this AI marketing name. Consensus still lags.

EA NewsletterEA Newsletter
The Lung-Drug Maker That Just Settled Its Way Out of a Patent Trap

The Lung-Drug Maker That Just Settled Its Way Out of a Patent Trap

A court ruling cut this stock in half. Then the lawsuit went away.

FirstBack
12345678
Next Last